From Financial Modeling Prep: 2025-06-16 16:04:00

Goldman Sachs sets a price target of $16 for NASDAQ:URGN, indicating a potential increase of about 33%. Despite legal hurdles, URGN’s stock price has seen a 12.01% increase, with a current trading price of $13.48. A class action lawsuit alleges securities fraud related to UroGen’s ENVISION clinical study, impacting the stock’s performance. UroGen Pharma Ltd. (NASDAQ:URGN) is a biopharmaceutical company focused on developing innovative therapies for urological diseases, known for its lead pipeline product, UGN-102, designed to treat low-grade upper tract urothelial cancer.



Read more at Financial Modeling Prep:: UroGen Pharma Ltd. (NASDAQ:URGN) Faces Legal Chall…